David F. McDermott, MD

Articles by David F. McDermott, MD

Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
View More
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Brian Rini, MD, FASCORenal Cell Carcinoma | October 30, 2024
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
Brian Rini, MD, FASCORenal Cell Carcinoma | October 30, 2024
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
Brian Rini, MD, FASCORenal Cell Carcinoma | October 30, 2024
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 30, 2024
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 30, 2024
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 29, 2024
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 29, 2024
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
Daniel Joyce, MDnccRCC | October 19, 2024
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
Daniel Joyce, MDnccRCC | October 19, 2024
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
Daniel Joyce, MDnccRCC | October 15, 2024
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
Daniel Joyce, MDnccRCC | October 15, 2024
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
Daniel Joyce, MDnccRCC | October 15, 2024
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
Brian Rini, MD, FASCORenal Cell Carcinoma | October 2, 2024
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
Thomas Powles, MBBS, MRCP, MDRenal Cell Carcinoma | October 2, 2024
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.